Home » Stocks » Merit Medical Systems

Merit Medical Systems, Inc. (MMSI)

Stock Price: $46.25 USD -0.31 (-0.67%)
Updated Aug 14, 2020 12:50 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.57B
Revenue (ttm) 962.87M
Net Income (ttm) -29.82M
Shares Out 55.48M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE 47.17
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $46.25
Previous Close $46.56
Change ($) -0.31
Change (%) -0.67%
Day's Open 46.43
Day's Range 45.94 - 46.85
Day's Volume 117,769
52-Week Range 19.50 - 47.99

More Stats

Market Cap 2.57B
Enterprise Value 3.01B
Earnings Date (est) Mar 2, 2021
Ex-Dividend Date n/a
Shares Outstanding 55.48M
Float 43.93M
EPS (basic) -0.54
EPS (diluted) -0.54
FCF / Share 0.87
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.88%
Payout Ratio n/a
Shares Short 4.57M
Short Ratio 9.27
Short % of Float 8.95%
Beta 1.06
PE Ratio n/a
Forward PE 47.17
P/FCF Ratio 53.19
PS Ratio 2.67
PB Ratio 2.70
Revenue 962.87M
Operating Income -23.92M
Net Income -29.82M
Free Cash Flow 48.25M
Net Cash -445.38M
Net Cash / Share -8.03
Gross Margin 44.90%
Operating Margin -2.48%
Profit Margin -3.10%
FCF Margin 5.01%
ROA 1.53%
ROE -3.17%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 5
Overweight 1
Hold 1
Underweight 1
Sell 1

Analyst Consensus: Overweight

Price Target

$51.38*
(11.09% upside)
Low
42.0
Current: $46.25
High
63.0
Target: 51.38
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue995883728604542510449394359297
Revenue Growth12.7%21.28%20.54%11.38%6.37%13.5%13.89%9.69%21.13%-
Gross Profit432395326265236225194182165128
Operating Income15.4358.6233.0734.8837.5440.1727.8429.6433.1917.20
Net Income5.4542.0227.5220.1223.8022.9716.5719.7123.0412.46
Shares Outstanding55.0852.2748.8144.4144.0443.1442.6142.1839.0935.29
Earnings Per Share0.100.780.550.450.530.530.390.460.580.35
EPS Growth-87.18%41.82%22.22%-15.09%0%35.9%-15.22%-20.69%65.71%-
Operating Cash Flow77.8186.5362.7353.6069.4653.3351.3746.9434.0234.76
Capital Expenditures-77.25-63.27-38.60-32.82-49.71-34.08-59.39-64.60-59.19-23.63
Free Cash Flow0.5623.2624.1320.7819.7519.24-8.02-17.66-25.1811.13
Cash & Equivalents44.3267.3632.3419.174.187.367.469.7210.133.74
Total Debt52439527832420822424923830.7481.54
Net Cash / Debt-479-328-246-305-203-217-241-228-20.61-77.80
Assets1,7571,6201,112943779747728705447369
Liabilities80768743544531331232332489.93134
Book Value950933676498466435406382357236
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Merit Medical Systems, Inc.
Country United States
Employees 6,000
CEO Fred P. Lampropoulos

Stock Information

Ticker Symbol MMSI
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: MMSI
IPO Date August 9, 1990

Description

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah.